Orgenesis (OTCMKTS:ORGS) posted its quarterly earnings data on Monday. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.26), Fidelity Earnings reports. The firm had revenue of $7.76 million for the quarter, compared to the consensus estimate of $6.38 million.
Shares of OTCMKTS ORGS traded down $0.14 during mid-day trading on Tuesday, reaching $4.66. 19,447 shares of the company’s stock traded hands, compared to its average volume of 29,530. The business has a 50-day moving average of $4.47. Orgenesis has a 1-year low of $3.78 and a 1-year high of $9.25.
Separately, Zacks Investment Research upgraded shares of Orgenesis from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th.
Orgenesis Company Profile
Orgenesis Inc is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company’s subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products.
Featured Story: Analyzing a company’s cash flow statement
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.